SEC Company Response from BIOMARIN PHARMACEUTICAL (BMRN) — May 16, 2005
BIOMARIN PHARMACEUTICAL INC
Date: May 16, 2005 · CIK: 0001048477 · Accession: 0001193125-05-109245
AI Filing Summary & Sentiment
Reasoning
Referenced dates: May 12, 2005
Letter
Division of Mergers and Acquisitions Division of Corporation Finance Washington, D.C. 20549 Re: BioMarin Pharmaceutical Inc. - Preliminary Proxy Statement on Schedule 14A Filed May 2, 2005 (File No. 0-26727)
Dear Mr. Panos:
BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), is writing to the Staff of the Securities and Exchange Commission (the “Staff”) in response to the Closing Statements contained in the letter of comments from the Staff dated May 12, 2005 (the “Comment Letter”) with respect to the Company’s Preliminary Proxy Statement on Schedule 14A (the “filing” or the “Proxy Statement”). Capitalized terms used and not defined herein have the meanings ascribed to each such term in the Proxy Statement.
Set forth below is the statement of the Company requested by the Staff in the Closing Statements of the Proxy Statement:
•
the Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the filing;
•
the Company acknowledges that Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
the Company acknowledges that it may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions with respect to the foregoing, please contact the undersigned at (415) 506-6307 or Gregory C. Smith of Skadden, Arps, Slate, Meagher & Flom LLP at (650) 470-4590.
Nicholas P. Panos, Esq.
U.S. Securities and Exchange Commission
May 16, 2005
Page 2
Very truly yours,
/s/ G. Eric Davis
Show Raw Text
CORRESP 1 filename1.htm SEC Letter [BioMarin Letterhead] May 16, 2005 Mr. Nicholas P. Panos Division of Mergers and Acquisitions U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4-6 Washington, D.C. 20549 Re: BioMarin Pharmaceutical Inc. - Preliminary Proxy Statement on Schedule 14A Filed May 2, 2005 (File No. 0-26727) Dear Mr. Panos: BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), is writing to the Staff of the Securities and Exchange Commission (the “Staff”) in response to the Closing Statements contained in the letter of comments from the Staff dated May 12, 2005 (the “Comment Letter”) with respect to the Company’s Preliminary Proxy Statement on Schedule 14A (the “filing” or the “Proxy Statement”). Capitalized terms used and not defined herein have the meanings ascribed to each such term in the Proxy Statement. Set forth below is the statement of the Company requested by the Staff in the Closing Statements of the Proxy Statement: • the Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the filing; • the Company acknowledges that Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and • the Company acknowledges that it may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions with respect to the foregoing, please contact the undersigned at (415) 506-6307 or Gregory C. Smith of Skadden, Arps, Slate, Meagher & Flom LLP at (650) 470-4590. Nicholas P. Panos, Esq. U.S. Securities and Exchange Commission May 16, 2005 Page 2 Very truly yours, /s/ G. Eric Davis Name: G. Eric Davis Title: Vice President, Corporate Counsel and Assistant Secretary cc: Gregory C. Smith (Skadden, Arps, Slate, Meagher & Flom LLP) 2